Literature DB >> 2165831

Low molecular weight heparins and hypoaldosteronism.

H Levesque1, S Verdier, N Cailleux, M C Elie-Legrand, A Gancel, J P Basuyau, J Y Borg, N Moore, H Courtois.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2165831      PMCID： PMC1663122          DOI： 10.1136/bmj.300.6737.1437

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Inhibition by heparinoid of aldosterone biosynthesis in man.

Authors:  J W Conn; D R Rovner; E L Cohen; J E Anderson
Journal:  J Clin Endocrinol Metab       Date:  1966-05       Impact factor: 5.958

2.  Effect of a sulfated mucopolysaccharide (R01-8307) on the zona glomerulosa of the rat adrenal gland.

Authors:  E C Abbott; F C Monkhouse; J W Steiner; J C Laidlaw
Journal:  Endocrinology       Date:  1966-03       Impact factor: 4.736

3.  Routine heparin therapy inhibits adrenal aldosterone production.

Authors:  R O'Kelly; F Magee; T J McKenna
Journal:  J Clin Endocrinol Metab       Date:  1983-01       Impact factor: 5.958

Review 4.  Drug-induced hyperkalemia.

Authors:  S P Ponce; A E Jennings; N E Madias; J T Harrington
Journal:  Medicine (Baltimore)       Date:  1985-11       Impact factor: 1.889

5.  Chlorbutol, a new inhibitor of aldosterone biosynthesis identified during examination of heparin effect on aldosterone production.

Authors:  S J Sequeira; T J McKenna
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958
  5 in total
  5 in total

1.  Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study.

Authors:  Olga H Torres; Nerea Hernandez; Esther Francia; Montserrat Barcelo; Jose Mateo; Domingo Ruiz
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  A low molecular weight heparin decreases plasma aldosterone in patients with primary hyperaldosteronism.

Authors:  N Cailleux; N Moore; H Levesque; H Courtois; M Godin
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

4.  Unfractionated heparin as a safe alternative in a case of low molecular weight heparin-induced thrombocytosis: A case report.

Authors:  Salem Jabira; Hassan Mitwally; Mohamed Saad; Edin Karic; Khaled Gazwi; Hani Elzeer; Moustafa Elshafei
Journal:  Ann Med Surg (Lond)       Date:  2021-04-30

5.  Heparin-induced hyponatremia in COVID-19: A latent culprit!

Authors:  Rajesh Panda; Pooja Singh; Saiteja Kodamanchili; Abhijeet Anand
Journal:  Indian J Pharmacol       Date:  2021 Nov-Dec       Impact factor: 1.200
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.